GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (STU:HDP1) » Definitions » Cyclically Adjusted FCF per Share

Arrowhead Pharmaceuticals (STU:HDP1) Cyclically Adjusted FCF per Share : €-0.95 (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Arrowhead Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.944. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.95 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -2.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Arrowhead Pharmaceuticals was 35.20% per year. The lowest was -2.70% per year. And the median was 20.75% per year.

As of today (2024-05-26), Arrowhead Pharmaceuticals's current stock price is €22.88. Arrowhead Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-0.95. Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.66 -0.62 -0.45 -0.58 -0.74

Arrowhead Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.63 -0.66 -0.74 -0.85 -0.95

Competitive Comparison of Arrowhead Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arrowhead Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.944/131.7762*131.7762
=-0.944

Current CPI (Mar. 2024) = 131.7762.

Arrowhead Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.148 100.560 -0.194
201409 -0.163 100.428 -0.214
201412 -0.367 99.070 -0.488
201503 -0.276 99.621 -0.365
201506 -0.201 100.684 -0.263
201509 -0.192 100.392 -0.252
201512 -0.332 99.792 -0.438
201603 -0.223 100.470 -0.292
201606 -0.282 101.688 -0.365
201609 -0.177 101.861 -0.229
201612 0.062 101.863 0.080
201703 -0.196 102.862 -0.251
201706 -0.138 103.349 -0.176
201709 -0.104 104.136 -0.132
201712 -0.167 104.011 -0.212
201803 -0.153 105.290 -0.191
201806 -0.143 106.317 -0.177
201809 -0.033 106.507 -0.041
201812 1.541 105.998 1.916
201903 -0.179 107.251 -0.220
201906 0.065 108.070 0.079
201909 0.054 108.329 0.066
201912 -0.258 108.420 -0.314
202003 -0.278 108.902 -0.336
202006 -0.310 108.767 -0.376
202009 -0.109 109.815 -0.131
202012 -0.346 109.897 -0.415
202103 2.076 111.754 2.448
202106 -0.267 114.631 -0.307
202109 -0.263 115.734 -0.299
202112 -0.568 117.630 -0.636
202203 0.488 121.301 0.530
202206 -0.701 125.017 -0.739
202209 -0.968 125.227 -1.019
202212 -1.019 125.222 -1.072
202303 -0.509 127.348 -0.527
202306 -0.587 128.729 -0.601
202309 -0.779 129.860 -0.790
202312 -1.592 129.419 -1.621
202403 -0.944 131.776 -0.944

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Arrowhead Pharmaceuticals  (STU:HDP1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (STU:HDP1) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Arrowhead Pharmaceuticals (STU:HDP1) Headlines

No Headlines